Q1 2025 Management View CEO Daniel O'Day highlighted a 4% growth in the base business excluding Veklury, led by a 6% ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Correction, April 10: This article has been updated to clarify differences between the once-yearly and twice-yearly formulations of lenacapavir. Lenacapavir for HIV prevention remains ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Since 2018, three medications have been approved by the FDA for use in heavily treatment-experienced or treatment-resistant HIV: ibalizumab, fostemsavir and lenacapavir.

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the ...

The list recognizes the impact, innovation, and achievement of the world’s most influential individuals. The drug, lenacapavir, was developed at Gilead Sciences, and is exceptionally effective at ...

O'Day emphasized the upcoming FDA decision for Lenacapavir for PrEP, expected by June 19, 2025, and its potential launch in the U.S. shortly thereafter. This is one of nine HIV product launches ...